Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.49 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846513 | 0.85 | GRIN2D (0.48) | HSD11B1HSD11B2EPHX2ALDH1A1TSHR | |
| SCHEMBL9948664 | 0.85 | GRIN2D (0.48) | HSD11B1HSD11B2EPHX2ALDH1A1TSHR | |
| SCHEMBL1846516 | 0.85 | GRIN2D (0.48) | HSD11B1HSD11B2EPHX2ALDH1A1TSHR | |
| SCHEMBL1846514 | 0.85 | GRIN2D (0.48) | HSD11B1HSD11B2EPHX2ALDH1A1TSHR | |
| SCHEMBL9949867 | 0.81 | HSD11B1 (0.38) | HSD11B1HSD11B2EPHX2ALDH1A1TSHR | |
| SCHEMBL4556735 | 0.79 | P2RX7 (0.55) | HSD11B1HSD11B2ESR1CYP2C9ESR2 | |
| SCHEMBL1844173 | 0.77 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| SCHEMBL9948713 | 0.77 | HSD11B1 (0.42) | HSD11B1HSD11B2EPHX2ALDH1A1TSHR | |
| SCHEMBL1844175 | 0.77 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| SCHEMBL1844176 | 0.77 | HSD11B1 (0.58) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536173-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | SANOFI (FR) | 2013-09-17 | — | — | US | disclosed |
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NR2C2, CBR3, NR0B2 | HSD11B1 1172/4885HSD11B2 991/4885ESR1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.